SLC26 family: a new insight for kidney stone disease

Frontiers in Physiology

Physiology

Quanliang Liu¹  Shengyin Liu²  Sheng Yan²  Sigen Huang²  Jialin Li²  Xinzhi Liao² 

[1] Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China;The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China;Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China;

关键词: SLC26;    kidney stone;    oxalate;    hyperoxaluria;    oxalate metabolism;   

DOI  :  10.3389/fphys.2023.1118342

 received in 2022-12-07, accepted in 2023-05-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

The solute-linked carrier 26 (SLC26) protein family is comprised of multifunctional transporters of substrates that include oxalate, sulphate, and chloride. Disorders of oxalate homeostasis cause hyperoxalemia and hyperoxaluria, leading to urinary calcium oxalate precipitation and urolithogenesis. SLC26 proteins are aberrantly expressed during kidney stone formation, and consequently may present therapeutic targets. SLC26 protein inhibitors are in preclinical development. In this review, we integrate the findings of recent reports with clinical data to highlight the role of SLC26 proteins in oxalate metabolism during urolithogenesis, and discuss limitations of current studies and potential directions for future research.

【 授权许可】

Unknown   
Copyright © 2023 Li, Huang, Liu, Liao, Yan and Liu.